Table 4.

Association between methamphetamine-associated PAH and HRQL

Instrument	Instrument Type	MCID	Mean Difference (95% CI)	P Value
Unadjusted
SF12-PCS	Generic-physical	5	1.7 (0.7 to 2.8)	0.001
SF12-MCS	Generic-mental	5	−3.8 (−5.3 to −2.4)	<0.001
emPHasis-10 (reverse coded)	PAH specific	6	−5.0 (−7.4 to −2.6)	<0.001
Adjusted for age, sex, race/ethnicity, education, body mass index, and the time-dependent covariate of whether the participant was on PAH-specific therapy or not
SF12-PCS	Generic-physical	5	0.8 (−0.4 to 2.0)	0.175
SF12-MCS	Generic-mental	5	−2.7 (−4.4 to −1.1)	0.001
emPHasis-10 (reverse coded)	PAH specific	6	−5.4 (−8.1 to −2.8)	<0.001

Definition of abbreviations: CI = confidence interval; HRQL = health-related quality of life; MCID = minimally clinically important difference; PAH = pulmonary arterial hypertension; SF12-MCS = Short Form 12-Mental Component Summary; SF12-PCS = Short Form 12-Physical Component Summary.

Data are presented as mean difference with 95% CIs between participants with methamphetamine-associated PAH as compared with participants with idiopathic PAH, as quantified by generalized estimating equations using a Gaussian distribution. Models were adjusted for age, sex, race/ethnicity, education, body mass index, and the time-dependent covariate of whether the participant was on PAH-specific therapy or not. HRQL instruments used include the SF12-PCS, the SF12-MCS, and the PAH-specific emPHasis-10. The emPHasis-10 instrument was reverse coded so that higher scores denote better HRQL in all HRQL instruments. Each instrument has its own MCID.